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Abstract
Background: The routes by which humans acquire influenza H5N1 infections have not been fully elucidated. Based on 
the known biology of influenza viruses, four modes of transmission are most likely in humans: aerosol transmission, 
ingestion of undercooked contaminated infected poultry, transmission by large droplets and self-inoculation of the 
nasal mucosa by contaminated hands. In preparation of a study to resolve whether H5N1 viruses are transmissible by 
aerosol in an animal model that is a surrogate for humans, an inhalation exposure system for studies of aerosolized 
H5N1 viruses in ferrets was designed, assembled, and validated. Particular attention was paid towards system safety, 
efficacy of dissemination, the viability of aerosolized virus, and sampling methodology.
Results: An aerosol generation and delivery system, referred to as a Nose-Only Bioaerosol Exposure System (NBIES), 
was assembled and function tested. The NBIES passed all safety tests, met expected engineering parameters, required 
relatively small quantities of material to obtain the desired aerosol concentrations of influenza virus, and delivered 
doses with high-efficacy. Ferrets withstood a mock exposure trial without signs of stress.
Conclusions: The NBIES delivers doses of aerosolized influenza viruses with high efficacy, and uses less starting 
material than other similar designs. Influenza H5N1 and H3N2 viruses remain stable under the conditions used for 
aerosol generation and sample collection. The NBIES is qualified for studies of aerosolized H5N1 virus.
Background
Human infections caused by highly pathogenic avian
influenza H5N1 viruses (H5N1) that arose from 2003-
onwards have been rare (495 cases confirmed through
April 21, 2010) but have a fatality rate of about 59% [1].
There is limited knowledge about the potential routes
and determinants required for H5N1 transmission to and
between humans. Human-to-human transmissions have
rarely been reported, and have been limited, inefficient
and un-sustained. In ferret transmission models, H5N1
are inconsistent in transmission by direct or indirect con-
tact exposure, but direct intranasal exposure causes mor-
bidity and sometimes, mortality (2, 3, and J. Lednicky,
unpublished). In contrast, the 1918 pandemic influenza
virus was easily transmissible human-to-human, and
caused the deaths of between 20 - 40 million people
worldwide for a lethality rate of 2.5%. Whereas the differ-
ences in transmissibility and lethality between the two
viruses are not fully understood, performing well-con-
trolled inhalation exposure studies of aerosolized viable
H5N1 in appropriate animal models may improve our
understanding of factors responsible for -the acquisition
of H5N1 infections by humans and the virulence/lethality
relative to route of transmission.
Four modes are most likely for the transmission of
influenza viruses: aerosol transmission, ingestion of
undercooked contaminated infected poultry, transmis-
sion by large droplets, and self-inoculation of the nasal
mucosa by contaminated hands. Various publications
state that large-droplet transmission is the predominant
mode by which infection by seasonal influenza A viruses
is acquired by humans [4-7], while others refer to aerosols
as an important mode of transmission for influenza [8-
12]. Transmission may also occur through direct contact
w i t h  s e c r e t i o n s  o r  f o m i t e s  w i t h  o r a l ,  c o n j u n c t i v a l  a n d
nasal mucus membranes because the virus can remain
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infectious on nonporous dry surfaces for ≤48 hours [13].
To date, transmission of H5N1 to humans has occurred
primarily through close contact with infected birds or, in
a single case, consumption of raw infected duck blood
[14]. There is some evidence for limited human to human
transmission of H5N1 [14-18]. Transmission of influenza
viruses by large droplets without accompanying aerosols
has been simulated by intranasal droplet infection [19]
and it is assumed that H5N1 infections may be acquired
through droplet transmission routes, since intranasal
inoculation of ferrets with H5N1 strains (used as a model
for droplet infection) can result in clinical signs of severe
influenza (3, 20, 21, 22, 23 and J. A.Lednicky, unpub-
lished). A basic understanding of how H5N1 is transmit-
ted to humans, and person-to-person, is valuable from a
public-health perspective, not only for establishing mea-
sures to protect community health, but also for the man-
agement of hospitalized patients.
Until the time of this work, it was not clear whether
humans could be infected through inhalation of aero-
solized contemporary H5N1 particles. Based on the natu-
ral biology of influenza viruses, we hypothesized that
clinically apparent infections could arise from inhalation
of aerosolized H5N1 viruses, and planned to test our
hypothesis using inhalation exposure studies of aero-
solized H5N1 in a ferret model. Here, aerosols are
defined as suspensions of small solid or liquid particles
(in air) that remain airborne for prolonged periods of
times due to their low settling velocity [6,24]. The settling
velocity in still air can be calculated using Stokes' law
[25], and the smaller the particle, the longer the settling
time.
There are two important considerations in studies of
bioaerosols generated by human subjects [12]. First, it is
important to distinguish between the initial diameter of
particles and the diameter after evaporation of water in
ambient air [the resulting desiccated particles are termed
'droplet nuclei'; for particles with an initial diameter <20
μm the evaporation occurs in <1 s [26,27] and the diame-
ter shrinks to a little less than half the initial diameter
[26]]. The second important consideration is penetration
of the respiratory tract by aerosolized particles. Particles
5 μm or less in aerodynamic diameter have a significant
penetration into the human respiratory tract all the way
to the alveolar region (30% penetration for 5 μm parti-
cles); particles ≥ 6 μm are increasingly trapped in the
upper respiratory tract [24,25,28]. Evaluation of particle
sizes are especially important for aerosol studies with
influenza virus: whereas human influenza viruses specifi-
cally recognize α2,6-linked sialic acid (SA) receptors,
which are dominant on epithelial cells in the upper respi-
ratory tract [29], contemporary H5N1 affecting humans
specifically recognize α2,3-linked SA receptors, which are
located in the lower respiratory tract [29,30]. These
receptors are not easily reached by the large droplets
(diameter of >10 μm) typically produced by coughing or
sneezing [4]. Noteworthy, penetration is not the same
thing as deposition. Due to a myriad of variables, only a
fraction of the penetrating particles may be deposited, the
remainder exhaled back [24,31].
Because some of the circulating H5N1 have demon-
strated uncharacteristic affinity for α2,6-linked SA recep-
tors and are therefore potentially dangerous to humans
[32,33], it is important to evaluate their airborne trans-
missibility in a suitable animal model. Domesticed ferrets
(Mustela putorius furo ) have respiratory tracts that share
many anatomic features with those of humans, and have
metabolic and physiologic similarities with humans. They
are an appropriate animal model [34] for study of the
pathogenicity [20,35] and transmissibility [36,37] of influ-
enza viruses. On the basis of H5N1 virus cell tropism in
their lower respiratory tract, ferrets have also been used
as a small animal model of human H5N1 pneumonia [30].
In preparation for studies of the transmissibility of
aerosolized H5N1 particles, we developed a nose-only
inhalation exposure system (NBIES) that can be used to
conduct studies with H5N1 and other influenza viruses in
ferrets (or other small animals). The NBIES configuration
described here produces aerosolized particles with diam-
eters appropriate for deep lung penetration. The assem-
bly and validation of the system are described in this
manuscript.
Results
1. NBIES overview
The NBIES is comprised of aerosol generation equip-
ment, animal holders, samplers, a class III glovebox, and
the pumps, flow meters, and other equipment required
for the control, balancing, and measurement of airflows
and aerosols. It is housed within an ABSL3-enhanced lab-
oratory. A schematic diagram of the NBIES is shown in
Figure 1. A nose-only system design was chosen over
whole-body and other exposure system designs for the
NBIES for the following reasons: (1) It minimizes the
establishment of infection by non-inhalation routes. The
probability of acquiring infection through non-inhalation
routes, such as ingestion of test agent deposited in fur
during whole-body exposure studies, is significantly
higher using other exposure systems, (2) It reduces the
requirements for post-exposure decontamination of ani-
mals. Otherwise, it is common practice to decontaminate
an animal with a bleach (or similar) solution during inha-
lation exposure studies using other types of dissemina-
tion devices, (3) It reduces potential contamination of
animal housing areas and animal care personnel. (4) It
permits testing with high concentrations of aerosolized
agent while minimizing quantities of starting material.
This is a useful feature when working with select agentsTuttle et al. Virology Journal 2010, 7:135
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in the USA, since their production and destruction are
performed following a cradle to grave documentation
process, and due to restrictions on the amounts of agent
that can be produced. To eliminate potential release of
aerosolized agent into the test facility, the exposure sys-
tem is operated under negative pressure relative to that of
the glove box, which is operated at negative pressure rela-
tive to the laboratory. System components located out-
side of the class III glovebox are routed through a
bulkhead panel using a series of one-way (check) valves
and HEPA filters attached in series.
2. Operational description
The NBIES functions in the following manner: high-pres-
sure air generated by an air compressor provides both
supply air for the generation of aerosols -and "dilution" air
used to create the desired aerosol concentration and flow.
Air supplied to the system is controlled at precise flow
rates and pressures with electronic and manual valves
and is metered using mass flow meters and controllers.
As air is supplied to the aerosol generator, a high velocity
air stream creates a venturi effect that siphons liquid
through a tube from the nebulizer reservoir that contains
the virus (or other agent) suspension. As the liquid exits
the tube at the top of the nebulizer, the air stream inter-
acts with the liquid and shears it creating a gas-phase
micron-sized aerosol stream. The size of the resulting
aerosol particles is a function of the air velocity regulated
by the air supply pressure and flow rate, and the volumet-
ric use rate of the nebulizer. From the nebulizer, a mini-
mally polydispersed aerosol stream travels into an
exposure system delivery tube, where additional filtered
dilution air is introduced upstream of the exposure sys-
tem to supply additional air for animal respiration, sam-
pling systems, humidity conditioning and control of the
aerosol challenge concentration. Ferrets are housed in
restraint tubes attached to the delivery ports of exposure
system and are positioned such that their muzzles are in
Figure 1 Schematic representation of the NBIES. Components outside (left) and inside (right) the glovebox are demarcated.
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close proximity to the ports from which the aerosol
stream is delivered for inhalation. The system is operated
in a dynamic (not static) mode; the aerosol stream passes
through the inhalation ports and exhausted through an
outer plenum of the exposure system. The exhaust system
consists of a valved exhaust pump equipped with HEPA
filters. The exhaust flow rate is regulated to maintain a
continuous negative pressure within the exposure system
relative to the class III glovebox and is monitored using a
Magnehelic differential pressure gauge. The system is
operated at air supply flow rates sufficient to provide a
continuous regeneration of fresh aerosol- stream to the
animals, reducing potential aerosol-stream and carbon
dioxide re-breathing concerns. Two of the exposure ports
are utilized during exposure challenges for real-time
measurement of aerosol particle size, and collection
(sampling) of aerosolized particles for viability counts.
The size distribution of aerosolized particles is measured
using an Aerodynamic Particle Sizer®  Spectrometer
(APS), and viable agent exposure challenge and dose con-
centrations are determined from the quantity of viable
test agent that is collected within impingers.
In the challenge-material preparation process, influ-
enza virus is mixed with a non-toxic delivery vehicle
(sterile PBS solution with 0.5% purified BSA fraction V)
to help maintain viability of the virus and act as a vehicle
to generate the aerosol stream. The saline solution is well
characterized and its acute inhalation toxicity known (it
does not cause an acute inflammatory response when
inhaled by ferrets in the quantities used in this work). An
antifoam agent is added to the starting material and col-
lector fluids in the impingers to reduce bubbling.
3. Validation of system engineering and function
Initial operating parameters of the exposure system were
based on ferret respiratory requirements, and sampling
system, particle size monitoring, and generation-system
flow-rate requirements, A commercial non-ionic deter-
gent solution (Snoop Leak Detector, Swagelok Co., Solon,
OH) was used to detect leaks in the air-handling and sys-
tem components after assembly of the NBIES. Leaks
detected (if any) were sealed and the system repeatedly
r e t e s t e d  t o  v e r i f y  r e m e d i a t i o n .  T o  i m p r o v e  s a f e t y  a n d
extend durability, plastic tubing and valves were replaced
with stainless steel equivalents where possible. During
the pre-study development phase, evaluation of the
NBIES included measurements of exposure port-to-port
aerosol concentration homogeneity, concentration
increase over time, aerosol concentration stability over
the exposure duration, and decline over time, which were
evaluated using calibrated National Institutes of Stan-
dards and Technology (NIST) - traceable polystyrene
latex (PSL) microspheres of three different sizes. For
these assays, measurements were taken using the APS.
Figure 2 (relevant data points in T able 1) shows a plot
representing the aerosol exposure port-to-port homoge-
neity comparing the aerosol concentration uniformity of
different-sized PSL microspheres delivered to each expo-
sure port (results of three separate trials). These experi-
ments to assess aerosol homogeneity did not require
uniform starting concentrations of the three different-
sized PSL suspensions; thus the total counts (aerosol con-
centration levels) for the different-sized PSL suspensions
vary in Figure 2 but are relatively uniform within a micro-
sphere size group. The slight variability (lower counts) for
port 1 (Figure 1 and Table 1) are due to the time lag when
moving the APS probe to port 1 in the glovebox, and are
not due to system design failure or problems.
Figure 3 depicts the results of size distribution homoge-
neity characterization tests; measurements of both num-
ber median diameter and geometric standard deviation
(GSD) are shown. The GSD is a measure of dispersion for
a log-normal distribution and is analogous to the stan-
dard deviation for a normal distribution. It is the ratio of
the 84.13 percentile to the 50 percentile, and aerosols
with GSD >1.2 are considered to be polydispersed (i.e.,
the particles vary significantly in size). As shown in Fig-
Table 1: Five minute aerosol characterization results for A/Wisconsin/67/2005 (H3N2).*
Virus Conc. (TCID50/ml) in 
BANG reservoir
Virus quantity in 
impinger A (TCID50 units)
Virus quantity in 
impinger B (TCID50 units)
Theoretical 100% 
recovery (TCID50 units)
Approximate collection 
efficiency impinger A
4.6 × 106 83 750 BLD** 92 000 91.0%
4.6 × 106 82 860 BLD 92 000 90.1%
4.6 × 106 89 990 BLD 92 000 97.8%
4.6 × 105 8 732 BLD 9 200 94.9%
4.6 × 105 8 197 BLD 9 200 89.1%
4.6 × 105 8 464 BLD 9 200 92.0%
*Running conditions: nebulizer use rate, 0.1 ml/min; generation time, 5 min; system total flow rate, 5 L/min; impinger sample rate, 1 L/min; 
impinger sample time, 5 min.
**BLD, below limits of detection.Tuttle et al. Virology Journal 2010, 7:135
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ure 3, the 1.8 μm particles, with a GSD of 1.29, are nomi-
nally polydispersed; the 1.0 and 3.0 μ microspheres are
nearly monodispersed (nearly unimodal). With the GSD
in the range of 1.2, and the median values indicating a
size distribution that centers on the PSL manufacturer's
specifications, this characterization data is acceptable
since it suggests the system is functioning as desired. The
data shows the port to port size distribution and GSD's of
select aerosol particle sizes generated from suspension do
not differ from port to port on the aerosol system. The
results indicate that aerosols generated from the nebu-
lizer (at the flow rates used for the NBIES for exposures)
deliver a dry and uniform particle size to each of the
NBIES' five ports. Therefore, inhalation (and presumably
lung deposition) of the generated aerosolized agent
should be similar for animals at any of the five locations.
Figure 4 depicts aerosol concentration trends for 5 min
characterization tests of the NBIES with three sizes of
uniform polystyrene microspheres; rapid ramp-up, stabil-
ity of aerosol concentration during dissemination, and
rapid decline at termination are evident. Evaluating these
properties of the aerosol system is important; deviations
from homogeneity affect accuracy during the delivery of
exposure doses, and the performance of reproducible
exposure trials.
4. Evaluation of aerosol vehicle
Based on cumulative experience (J. Lednicky, unpub-
lished), an aerosol vehicle comprised of (PBS + 0.5% BSA
+ antifoam agent media) was prepared and tested. Influ-
enza virus is suspended in the aerosol vehicle (which is
designed to maintain the virus' viability for several hours
at room temperature), and the suspension added to the
nebulizer reservoir prior to creation of the aerosol stream
that disperses and delivers the virus. Virus viability was
shown stable at room temperature over a period of three
hours in the aerosol vehicle (data not shown).
Thereafter, the aerosol size distribution of the aerosol
vehicle was characterized. Tests indicated a particle size
distribution including a range needed for deep lung pene-
tration (data not shown). The PBS + 0.5% BSA + antifoam
agent media was also utilized as the aerosol-stream col-
lection media for impinger samplers.
5. System integrity and safety test using live agent
A safety test was performed as part of the system valida-
tion process with live-agent dissemination of Influenza
virus  A/Wisconsin/67/2005 (H3N2) [Wis/05]. No
releases were detected by environmental sampling for live
agent (data not shown).
Figure 4 Port to port concentration vs time profile. Counts were 
taken from a sampled volume of 0.33 liters of aerosol stream at 20 sec 
intervals.
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7. Particle size analyses of aerosolized Wis/05
Wis/05 was aerosolized starting with three different con-
centrations of virus, and the sizes of the particles gener-
ated were analyzed. The results are depicted in an aerosol
particle-size log-probability plot in Figure 5. The mean
mass aerodynamic diameter (MMAD), which is the
diameter that divides the frequency of particles in half,
ranges from 3.41 to 4.11 μ, indicating a significant pro-
portion of particles of the size needed for deep lung pene-
tration (≤5 μ) were present.
8. Evaluation of impinger performance
Precision in calculations of aerosol concentrations and
estimates of the number of viruses inhaled per experi-
ment depend largely on the collection efficiency/efficacy
of the sampler(s). Therefore, the sampling system must
first be characterized to establish operational parameters
determined to obtain a presented dose (D ) (defined as
the inhaled dose estimated from the multiplication of the
aerosol concentration and the total volume of air
breathed in by an animal). D is estimated from an ani-
mal's respiratory rate and the duration of its exposure to
aerosolized agent. Systems similar to the NBIES are often
designed with a single impinger and are operated with the
assumption that > 90% of the aerosolized microorganisms
are entrained (trapped) during sampling of the aerosol
flow through the sampler, and that collection is represen-
tative of the viable inhaled dose and retention in the ani-
mal model. If the efficiency of the collector is not known,
a significant undercount of the aerosol concentration can
result, causing both an underestimate of the inhaled dose
and an overestimate of virulence (since the number of
organisms to cause an infection is undercounted). More-
over, the collection fluid in the impinger must maintain
the aerosolized agent in a viable (infectious) manner and
q u a n t i f i c a t i o n  s h o u l d  b e  f o r  v i a b l e  a g e n t .  O t h e r w i s e ,
quantification of aerosolized agent based solely on bio-
chemical or immunological assays (such as PCR or
ELISA) may complicate and confound understanding by
measuring both live and inactivated agents. Although the
effect of the collection process on the viability of the
entrained agent in the impingers can only be inferred,
collection efficency of our sampling system using funda-
mental mathematics could be derived. The NBIES was
designed with a dual impinger arrangement based on pre-
vious experience (Richard Tuttle, unpublished). The
impingers selected were low collection flow, low velocity
collectors that apply minimal collection forces (e.g.
impaction and turbulence) on the aerosolized agent dur-
ing the collection process. Thus, they reduce the impact
of compromising the viability of the collected organism in
relation to other collectors that are typically used in bio-
aerosol studies. By using a dual impinger collection sys-
tem with primary and secondary impingers sampling in-
parallel and in-series, it was discovered that aerosolized
Influenza virus A/Vietnam/1203/2004 (H5N1) [VN/04]
was not collected with high efficiency with one impinger
alone under the conditions used, whereas Wis/05 was
largely entrained by one impinger (results for 5 min test,
Table 1). In contrast, VN/04 was not entrained effectively
by the primary impinger alone (examples shown in Tables
2 and 3). A possible explanation is that primary isolates of
influenza viruses are often filamentous, whereas labora-
tory strains appear more spherical to ovoid, and thus
their physical characteristics are somewhat different. The
H 5 N 1  s t r a i n  u sed  i n  t h i s  w o r k  is  fi la m e n t o u s.  O n c e  a
virus is aerosolized and "dry", it may become hydropho-
bic and hard to rehydrate, decreasing collection in
impinger media, and it may be harder to rehydrate a long
filamentous influenza virus particle. In support of this
notion, there was no detectable virus in impinger B when
impinger A was spiked with VN/04 and the NBIES oper-
ated for 5 or 10 min (data not shown).
9. Sham run with ferrets
Ferrets were tested using sham 10-min runs. No prob-
lems were encountered; there was no evidence of heat
stress, or indications of improper airflow control (such as
cyanosis resulting from CO2 build-up). No reddening of
the skin (another indicator of stress) was detected. Ferrets
did not seem agitated upon release from the exposure
system and rapidly resumed normal activity.
Conclusions
The data trends shown in Figures 2 to 4 depict desirable
results for an aerosol system that delivers reproducible
and accurate aerosol challenges with precision and accu-
racy. The data shows uniform delivery of aerosol concen-
tration at each exposure-location, rapid increase to
Figure 5 Aerosol size log-probability plot for Wis/05. The MMAD 
and GSD are indicated at three different concentrations of virus and for 
the control solution.
Buffer control, MMAD = 3.46  m, GSD = 1.86
Wis/05; 1exp4 IVP/ml, MMAD = 3.41  m, GSD = 1.98
Wis/05; 1exp5 IVP/ml, MMAD = 3.61  m, GSD = 2.06
Wis/05; 1exp6 IVP/ml, MMAD = 4.11  m, GSD = 2.06Tuttle et al. Virology Journal 2010, 7:135
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stable-state concentration, stable aerosol delivery over
time, and a rapid decrease or purge of the aerosol from
the system after the exposure challenge is terminated.
Doses of influenza viruses were delivered at efficiencies
ranging from 9 - 98% (sample data shown in Tables 1, 2,
and 3). Due to a paucity of data, direct comparisons of the
delivery of influenza viruses with other systems are diffi-
cult. However, similar systems typically deliver various
types of doses with lower efficiencies, such as ~0.05% for
a one-jet Collison nebulizer at an air pressure of 5 psig
[38]. Thus, the NBIES is highly effective. Experiments
with VN/04 clearly indicate that an undercount of the
aerosolized virus can occur if only one impinger is used.
Two or more impingers should be used for accuracy/pre-
cision. Otherwise, incorrect estimates of delivered dose
and analyses of system efficiency occur.
The particle size measurements showed consistent
aerosolized particle delivery (for all four dose groups)
that centered on a size range that should be respired and
deposited in the lower respiratory tract of humans. There
was little difference in particle size-distribution and
median diameter of the buffer control alone in compari-
son to aerosolized virus. This suggests the possibility that
an influenza virion can be encapsulated within the salt-
BSA complex without greatly affecting the overall dimen-
sion of the aerosolized particle. However, there is no for-
mal proof that the particles detected by the APS indeed
contained virus (the virus may have aerosolized as free
virus particles with size below the detection limit of the
instrument).
The NBIES exposure port flow velocity (0.234 m/s) is
relatively low (~0.52 m/hr or ~0.84 km/hr); therefore
undue stress caused by airstream velocity in the region of
the animal's muzzle is not an issue. The volume of air
space in front of the animals nose (approx. 12.9 ml) is
small and changes frequently relatively to the volume of
air delivered/min for each port (Q port ); thus, re-breathing
of exhaled air and old (residual) aerosolized viral particles
should not occur. The system flow rate Q sys of 5 L/min
surpasses the calculated V m for 5 animals by a factor of
about 2.9× with a high estimate of 0.345 L/min for V m ,
and a factor of 5× with a value of 0.2 L/min. The same val-
ues apply to air changes; at 0.345 L/min, the number of
air changes required is 0.345 L/min × 5/0.101 L = ~17.1,
since there are 49.4 changes/min, ~2.9 air changes occur,
showing that more than adequate airflow is supplied to
the system for respiration and replenishment of fresh
aerosol in the respiration zone of the animal. Adequate
air flow is important for performing accurate inhaled
dose calculations as well as for the reduction of stress due
to the inhalation of increased CO2  levels that occurs
when air is re-breathed.
Finally, for comparison, it is also important to evaluate
the effects of inhaling large particle (~10 - 20 μm) aero-
sols (of influenza viruses). The NBIES is inappropriate for
that application; a different aerosol generator, such as a
spinning-top monodisperse aerosol generator in conjunc-
tion with an appropriate delivery system, are needed for
such a study.
Methods
1. Class III glovebox
A class III IsoGARD® Glovebox (The Baker Company,
Sanford, ME) was used to house the NBIES. The class III
glovebox has a High Efficiency Particulate Air (HEPA)-
Table 2: Five minute aerosol characterization results for A/Vietnam/1203/2004 (H5N1).*
Virus Conc. (TCID50/ml) 
in BANG reservoir
Virus quantity in 
impinger A (TCID50 units)
Virus quantity in 
impinger B (TCID50 units)
Theoretical 100% 
recovery (TCID50 units)
Approximate collection 
efficiency impingers A + B
4 600 000 10 450 9 975 92 000 22.2%
*Running conditions: nebulizer use rate, 0.1 ml/min; generation time, 5 min; system total flow rate, 5 L/min; impinger sample rate, 1 L/min; 
impinger sample time, 5 min.
Table 3: Ten minute aerosol characterization results for A/Vietnam/1203/2004 (H5N1) with three impingers.*
Virus Conc. 
(TCID50/ml) in 
BANG reservoir
Virus quantity in 
impinger A 
(TCID50 units)
Virus quantity in 
impinger B 
(TCID50 units)
Virus quantity in 
impinger C 
(TCID50 units)
Theoretical 
100% recovery 
(TCID50 units)
Approximate 
collection 
efficiency 
impingers 
A+B+C
4 600 000 19 665 19 665 10 165 184 000 26.9%
*Running conditions: nebulizer use rate, 0.1 ml/min; generation time, 10 min; system total flow rate, 5 L/min; impinger sample rate, 1 L/min; 
impinger sample time, 10 min.Tuttle et al. Virology Journal 2010, 7:135
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filtered primary chamber and a HEPA filtered pass-thru
chamber.
2. NBIES components
Most major components of the NBIES were purchased
from CH Technologies, USA, Westwood, NJ,, including
the aerosol generator and delivery system, exposure sys-
tems, and ferret restraint tubes with push rods, The aero-
sol delivery system includes a breathing air quality Jun-
Air compressor (model OF302-25BD2) for system air
supply positioned outside the glovebox, and a BioAerosol
Nebulizing Generator (BANG), (BGI Inc.)., Waltham,
MA). The BANG is a low flow, low dead space nebulizer
that is operated in the range of 1 to 4 liters per minute. It
was selected over other bio-aerosol generators as an
appropriate device for the aerosolization of influenza
virus. Considerations for selecting the BANG included:
minimal potential damage to agent, reduced clumping of
virus, uniformity of droplet size distribution, and effi-
ciency (lower use rate and volume of virus suspension
than that required by similar bio-aerosol generators). The
aerosol exposure system is a five-port nose-only design
manufactured out of polysulfone for chemical resistance
with clear plexiglass nose only ferret restraint holders. A
model 3314 APS (TSI Inc. St. Paul, MN) was used with
the NBIES. The APS is used to measure the aerosol size
distribution, and is capable of measuring aerosols in the
range of 0.3 to 20 μm. The APS is operated with Aerosol
Instrument Manager software, release version 8.0.0.0
(TSI, Inc.) run with a Dell Latitude D600 computer. The
exposure, generation, sampling, and particle size analysis
components of the system are located inside of the class 3
cabinet.
3. Regulation of exposure system negative pressure
During exposure challenges, the exposure system is regu-
lated at a negative pressure of approximately 0.05 to 0.1
inch of water, which is monitored using a magnehelic dif-
ferential pressure gauge (Dwyer Instruments, Inc), with
temperature in the range of 20 - 25°C and relative humid-
ity regulated in the range of 25 to 35 percent.
4. Temparature and humidity measurements
The temperature and humidity within the glovebox are
monitored using a model 11-661-19 digital temperature
and humidity monitor (Thermo Fisher Scientific,
Waltham, MA).
5. Monitoring and control of system flow rate
Mass flow meters (0 - 4 L/min from Dwyer Instruments,
Inc., Ivyland, PA) and a mass flow controller (Alicat Sci-
entific, Tucson AZ) are used for system flow rate moni-
toring and control.
6. Sampling system
The sampling system consists of two model 7531 midget
impingers (Ace Glass Incorporated, Vineland, NJ) con-
nected in series, with sample flow rates controlled using a
valve and monitored using a 0 - 5 L/min mass flow meter.
The sampler vacuum was created using a model 400-1901
Air Cadet Pump (Barnant Company, Thermo Fisher Sci-
entific).
7. Exhaust system
Airflow is drawn into the exhaust system by a 1/5-hp vac-
uum pump (Gast Manufacturing, Benton Harbor, MI)
and exhausted through two HEPA (High Efficiency Par-
ticulate Air) capsule filters (Pall Gelman, East Hills NY)
connected in series.
8. Impinger tests
Various tests were performed (details to be presented
elsewhere). Tests included entrainment testing of the of
aerosolized virus in collection media as well as spike tests
to determine whether virus captured in the primary
impinger (A) might be re-aerosolized and captured in the
secondary impinger (B).
9. Establishment of operational parameters unique to the 
NBIES
For this study, conditions were established that resulted
in >90% collection of live agent in the primary impinger
with the H3N2 virus. To evaluate the viable aerosol deliv-
ery efficiency and define operation parameters of the
aerosol exposure system, calculations based on (theoreti-
cal) 100% efficacy of aerosol dissemination were derived
using the following steps:
(1) Assuming 100% efficiency, the quantity of aero-
solized virus particles (VP) for a given C s is calculated 
as:
(2) The conc. of virus in impinger A for a given C s is 
calculated.
(3) The conc. of virus in impinger B is calculated for 
the same C s in step 2
(4) The volume sampled by both impingers (V i ) for t 
exp is calculated (for this work, 1 L/min × 10 min = 10 
L)
(5) Even dissemination by the system is assumed 
(based on system tests) and the apparent concentra-
tion of virus (C app ) in the aerosol stream is calculated 
as:
VP ml / min =× × Ct s neb flowrate( ) (min)
CV app i =+ sumof virusrecoveredinimpingers A B () /Tuttle et al. Virology Journal 2010, 7:135
http://www.virologyj.com/content/7/1/135
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(6) The volume disseminated by the system (V s ) is 
calculated as = System flow rate × t exp 
(7) At 100% efficiency, the concentration of VP in the 
aerosol stream (C aero ) is: VP/V s 
(8) The true efficiency (expressed as %) of the system 
is: C app /C aero × 100
(9) D = C app × V m × t exp 
10. Operational parameters
The NBIES was operated using the following parameters:
 Exposure time (amount of time an animal is 
exposed to aerosolized influenza virus) = texp = 10 
min
 System head pressure (pressure supplied by Jun air 
compressor) = 30 psi = 206842.8 Nm-2
 Total system flow rate (aerosol flow rate) over 5 
ports = Qsys = 5 L/min
 Flow rate per system exposure port = Qport = 5 L/
min/5 ports = 1 L/min
 Nebulizer pressure = PBANG = 26 psi = 179263.76 
Nm-2 (the pressure is lower than the system head 
pressure due to slight pressure loses that normally 
occur in air-handling systems)
 Aerosol generation rate ("use rate") (volume of liq-
uid generated by the nebulizer/time) = 0.1 mL/min
 Relative humidity: 25 to 35%
 Temperature: 20 - 25 C
 Negative pressure system: 0.05 to 0.1 inches water 
(~0.002 to 0.004 psi, or ~12.45 to 24.9 Nm-2).
 Viable sample collection (10 ml collection fluid/
impinger)
 Impinger sample flow rate = Q imp = 1 L/min
 APS sampling rate Q APS = 1 L/min
 Times were measured with electronic stopwatches.
11. Assessments of exposure system port to port aerosol 
concentration homogeneity
Exposure port to port concentration homogeneity (Figure
2) was evaluated in trials with NIST-traceable PSL micro-
spheres. PSL beads with diameters of 1.09, and 1.83 μm
(Polysciences, Inc., Warrington, PA), and 3.0 μm (Duke
Scientific Corporation, Palo Alto, CA) were suspended in
tissue-culture grade deionized H2O, and separately aero-
solized using the BANG nebulizer. The total number of
aerosolized particles detected every 20 sec by the APS
was used to define aerosol concentration.
12. Aerosol particle size homogeneity
Aerosol particle size and concentration (Figure 3) were
analyzed as for item 11 (above) using the APS.
13. Starting material and impinger fluid
Virus was diluted to the appropriate concentration in the
aerosol vehicle (PBS + 0.5% BSA fraction V), and molecu-
lar-grade antifoam agent B (Sigma-Aldrich, Inc., St.
Louis, MO) added at 0.25% (v/v). After mixing, 4 ml of
the virus + antifoam material was placed in the nebulizer
reservoir. Similarly, 10 ml of PBS + 0.5% BSA fraction V
but with 0.5.% (v/v) antifoam agent B was placed into
each impinger for aerosol collection.
14. Viruses
Influenza A virus VN/04 was obtained from the United
States Department of Agriculture Southeast Poultry
Research Laboratory (USDA SEPRL, Athens, GA). Per-
mits necessary for the importation and work with H5N1
viruses were acquired in accordance with federal, state,
and local laws. Influenza A virus Wis/05 was obtained
from the Centers of Disease Control and Prevention
(CDC). The identity of the viruses was established using
viral genomic sequencing.
15. Bio-containment facilities
In-vitro and in vivo experiments with H5N1 viruses were
conducted in USDA-approved BSL3 and animal biologi-
cal safety level 3-enhanced (ABSL3 -enhanced) contain-
ment facilities, respectively, and required use of personal
protective equipment and occupational health monitor-
ing program.
16. In-vitro cell growth and manipulations
Pilot studies indicated that the infectivity of the viruses of
this work was higher in an MRI validated Mustela vison
(mink) lung (Mv1 Lu) cell line than in a Madin Darby
canine kidney (MDCK) cell line that is used more com-
monly for influenza virus work (data to be presented else-
where). The Mv1 Lu cells were propagated in Eagle's
Minimal Essential Medium (EMEM) supplemented with
L-Alanyl-L-Glutamine (GlutaMAX™, Invitrogen Corp.,
Carlsbad, CA), penicillin, streptomycin, neomycin (Invit-
rogen Corp.), bicarbonate, sodium pyruvate, and gamma-
irradiated fetal bovine serum (HyClone, Pittsburgh, PA).
The viruses were titered in Mv1 Lu cells in serum-free
EMEM supplemented with bicarbonate, pyruvate, antibi-
otics, and L-1-tosylamido-2-phenylethyl chloromethyl
ketone (TPCK)-treated mycoplasma- and extraneous
virus-free trypsin (Worthington Biochemical Company,
Lakewood, NJ) in 5% CO2 at 37°C (VN/04) or 35°C (Wis/
05). The TPCK-trypsin used for this work had higher spe-
cific activity than TPCK-trypsin acquired elsewhere (data
not shown), and was used at a final concentration of 0.1
μg/ml. The 50% tissue culture infectious dose (TCID50)
were calculated by the Reed-Muench method [39].
17. Propagation of VN/04 in embryonating chicken eggs
VN/04 was propagated in the allantoic cavity of 10 day-
old SPF Chicken anemia virus (CAV)-free embryonating
chicken eggs (Charles River Laboratories, Wilmington,
MA) [40-42].Tuttle et al. Virology Journal 2010, 7:135
http://www.virologyj.com/content/7/1/135
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18. Sham inhalation exposure of ferrets
Studies were performed using descented, spayed 3-
month-old female ferrets (0.5 - 0.9 kg) (Triple F Farms,
Sayre, PA). Room conditions for all work included 12 hr.
light cycles, and an average relative humidity at 30%
within a room temperature range between 64° and 84°F
(17.8° to 28.9°C). The animals were fed pelleted ferret
food (Triple F Farms) and watered ad libitum, and
housed and maintained under applicable laws and guide-
lines with appropriate approvals from the Midwest
Research Institute Animal Care and Use Committee.
Conscious ferrets were used for the inhalation studies.
Prior to performing the study, the ferrets we acclimated
to the exposure tubes over a two day period. During the
study, all work was performed expeditiously to minimize
stress, and animals were moved in and out of the ferret
restraint tubes relatively quickly. Just prior to exposure,
the animals were loaded into the exposure restraint tubes
and quickly transported to the class III glovebox housing
the inhalation exposure system. The tubes were affixed
onto designated inhalation ports on the NBIES, the aero-
sol challenge generated, and the animals exposed accord-
ing to experimental design.
19. Calculations and definitions for aerosol transmission 
studies with ferrets
By convention used in aerobiology, where R refers to res-
piration rate, C refers to the concentration of aerosolized
agent, f(t) = % of agent deposited in the lungs, and t exp =
exposure duration time. When the following assumptions
are made: a constant minute volume (Vm) for R(t), a con-
stant live-agent aerosol concentration (integrated air
sample determined concentration for C(t), 100% deposi-
tion for f(t), and t(exp) is fixed at the time of exposure,
then: D = R × C × t exp .
The ferret respiratory minute volume (Vm), defined as
the volume of air inhaled or exhaled over a minute, can be
estimated using Guyton's formula [43], where BW = body
weight in gr, and the volume calculated in ml:
The ferrets chosen for mock exposure studies ranged
from about 500 to 900 gr. For a 500 gr ferret, log10BW3/4 =
0.75 × log10500 = 2.02. The antilog of 2.02 = 105.7; there-
fore, Vm = 2.10 × 105.7 = 222.0 ml/min (0.22 L/min). Sim-
ilarly, for a 900 gr ferret, Vm = 345.1 ml/min. Since most
of the ferrets were close to 500 gr, an approximate Vm
value of 0.2 L/min was used for this work. The Vm value
of 0.2 L/min used in this work was consistent with esti-
mates obtained by multiplying the ferret tidal volume (Vt)
expressed in ml × the breathing rate (BR) of conscious
ferrets expressed as breaths/minute (bpm). By definition,
Vt = the volume of air inspired or expired with each nor-
mal breath, whereas BR = number of breaths/minute
(bpm) for a conscious ferret. For ferrets, Vt = 6.06 ± 0.30
ml, and BR = 33 - 36 bpm [44,45].
Using an average Vt value of 6.06 ml and an average BR
of 34.5 bpm, Vm = 209.01 ml/min = 0.21 L/min.
For live agent work, the concentration of virus in the
aerosol stream is estimated from the virus collected in
impingers 1 and 2, where Q agi 1+2 is the collection flow
rate in L/min through impingers (agi ) 1 and 2, is:
The predicted respiratory volume during exposure (V e )
is calculated as:
The aerosol concentration (C aero ) needed to attain D is
calculated as: V e C aero = D 
Competing interests
The authors declare that they have no competing interests.
Authors' contributions
RST helped design and assemble the NBIES, established and protocols for inha-
lation exposure studies, helped with calculations, led efforts on the testing and
validation of the NBIES, assisted with data interpretation, and co-wrote the
manuscript; WAS assisted with the assembly, testing, and validation of the sys-
tem, and oversaw animal work; DED assisted with program management, in-
vitro virus work, and data interpretation; SBH established accurate virus quanti-
fication procedures, performed in-vitro virus work, and assisted with data inter-
pretation; JAL conceived the overall NBIES design including choice of BANG
nebulizer (with the assistance of all parties mentioned in the Acknowledg-
ments section), interpreted data, established calculations, provided oversight,
and co-prepared the manuscript. All authors read and approved the final man-
uscript.
Acknowledgements
The following NBACC scientists provided significant guidance and technical 
input in this project: Drs. Matthew Bender, Elizabeth Leffel (presently at Phar-
mAthene, Annapolis, MD), Michael Kuhlman (presently at Battelle Memorial 
Institute, OH), Richard Kenyon and Kenneth Tucker. Dr. Claire Croutch assisted 
in the development of the ferret model. The project team is grateful to Dr. 
Kevin King (presently at Diagnostic Hybrids, Inc., OH) for assistance in regula-
tory affairs and system validations, and to Dr. Barry Astroff (MRI) for assistance in 
establishing a dedicated aerosol facility for inhalation exposure studies. Drs. 
Chad Roy (Tulane Univ., LA) and Justin Hartings (Biaera Technologies, MD) are 
thanked for their early input into system design and equipment purchase. Dr. 
Rudolph Jaeger and Bridgett Corbett (CH Technologies, Inc.) provided invalu-
able assistance in equipment selection, system design, and assembly. The 
safety oversight of Eric Jeppesen, manager of the MRI Biosafety/Biosurety 
Office, is greatly appreciated. Upper management at MRI is thanked for provid-
ing the facility, class III glovebox, and aerosol generating equipment used in 
VB W B W m =× =× 21 0 21 0
34 07 5 ..
/.
VV B R mt =×
C
CxV agi CxV agi
Qagi xt
aero =
+
+
[( ) ( ) ] 12
12 exp
VV t em =× durationof exposure( ) expTuttle et al. Virology Journal 2010, 7:135
http://www.virologyj.com/content/7/1/135
Page 11 of 12
this project. This project was performed at the MRI Influenza and Respiratory 
Pathogen Research Center in Kansas City, and was partly funded by a coopera-
tive teaming agreement between MRI and the USDA/NBACC, by MRI develop-
ment funds, and by an MRI Internal Research and Development award to Dr. 
John Lednicky.
The technical support provided by the following individuals at MRI is greatly 
appreciated: Jane Morrissey and Micah Halpern.
Author Details
1Aerosol Research and Engineering Laboratories, 13300 West 98th Street, 
Lenexa, Kansas, 66215, USA and 2Energy and Life Sciences Division, Midwest 
Research Institute, 425 Volker Boulevard, Kansas City, Missouri 64110, USA
References
1. Cumulative Number of Confirmed Human Cases of Avian Influenza A/
(H5N1) Reported to WHO   [http://www.who.int/csr/disease/
avian_influenza/country/cases_table_2010_04_21/en/index.html]
2. Maines TR, Chen L-M, Matsuoka Y, Chen H, Rowe T, Ortin J, Falcón A, Hien 
NT, Mai LQ, Sedyaningsih ER, Harun S, Tumpey TM, Donis RO, Cox NJ, 
Subbarao K, Katz JM: Lack of transmission of H5N1 avian-human 
reassortant influenza viruses in a ferret model.  Proc Natl Acad Sci USA 
2006, 103:12121-12126.
3. Yen H-L, Lipatov AS, Ilyushina NA, Govorkova EA, Franks J, Yilmaz N, 
Douglas A, Hay A, Krauss S, Rehg JE, Hoffmann E, Webster RG: Inefficient 
Transmission of H5N1 Influenza Viruses in a Ferret Contact Model.  J 
Virol 2001, 81:6890-6898.
4. Bridges CB, Kuehnert MJ, Hall CB: Transmission of influenza: implications 
for control in health care settings.  Clin Infect Dis 2003, 37:1094-1101.
5. Garner JS: Guideline for isolation precautions in hospitals. The Hospital 
Infection Control Practices Advisory Committee.  Infect Control Hosp 
Epidemiol 1996, 17:53-80.
6. Tellier R: Review of aerosol transmission of influenza A virus.  Emerg 
Infect Dis 2006, 12:1657-1660.
7. World Health Organization Writing Group: Nonpharmaceutical 
interventions for pandemic influenza, international measures.  Emerg 
Infect Dis 2006 [http://www.cdc.gov/ncidod/EID/vol12no01/05-
1370.htm].
8. Cox NJ, Ziegler T: Influenza viruses.  In Manual of Clinical Microbiology 8th 
edition. Edited by: Murray PR, Baron EJ, Jorgensen JH, Pfaller MA, Yolken 
RH. Washington: ASM Press; 2003:1360-1367. 
9. Hayden FG, Palese P: Influenza virus.  In Clinical Virology 2nd edition. 
Edited by: Richman DD, Whitley RJ, Hayden FG. Washington: ASM Press; 
2002:891-920. 
10. Treanor JJ: Influenza virus.  In Mandell, Douglas and Bennett's principles 
and practice of infectious diseases 6th edition. Edited by: Mandell GL, 
Bennett JE, Dolin R. New York: Elsevier Churchill Livingstone; 
2005:2060-2085. 
11. Wagner R, Matrosovich M, Klenk HD: Functional balance between 
haemagglutinin and neuraminidase in influenza virus infections.  Rev 
Med Virol 2002, 12:159-166.
12. Wright PF, Webster RG: Orthomyxoviruses.  In Fields virology 4th edition. 
Edited by: Knipe DM, Howley PM, Griffin DE, Lamb RA, Martin MA, 
Roizman B. Philadelphia: Lippincott Williams & Wilkins; 2001:1533-1580. 
13. Bean B, Moore BM, Sterner B, Peterson LR, Gerding DN, Balfour HH Jr: 
Survival of influenza viruses on environmental surfaces.  J Infect Dis 
1982, 146:47-51.
14. The Writing Committee of the World Health Organization (WHO) 
Consultation on Human Influenza A/H5: Avian influenza A (H5N1) 
infection in humans.  N Engl J Med 2005, 353:1374-1385.
15. Eurosurveillance: Avian influenza H5N1 outbreaks in Romanian and 
Danish poultry, and large H5N1 cluster in an Indonesian family.  
Eurosurveillance 2006, 11:E060525.1 [http://www.eurosurveillance.org/
ew/2006/060525.asp#1].
16. Ungchusak K, Auewarakul P, Dowell SF, Kitphati R, Auwanit W, 
Puthavathana P, Uiprasertkul M, Boonnak K, Pittayawonganon C, Cox NJ, 
Zaki SR, Thawatsupha P, Chittaganpitch M, Khontong R, Simmerman JM, 
Chunsutthiwat S: Probable person-to-person transmission of avian 
influenza A (H5N1).  N Engl J Med 2005, 352:333-340.
17. Wang H, Feng Z, Shu Y, Yu H, Zhou L, Zu R, Huai Y, Dong J, Bao C, Wen L, 
Wang H, Yang P, Zhao W, Dong L, Zhou M, Liao Q, Yang H, Wang M, Lu X, 
Shi Z, Wang W, Gu L, Zhu F, Li Q, Yin W, Yang W, Li D, Uyeki TM, Wang Y: 
Probable limited person-to-person transmission of highly pathogenic 
avian influenza A (H5N1) virus in China.  The Lancet 2008, 
371:1427-1434.
18. Yang Y, Halloran ME, Sugimoto JD, Longini IM: Detecting human-to-
human transmission of avian influenza A (H5N1).  Emerg Infect Dis 2007, 
9:1348-1353.
19. Douglas RG: Influenza in man.  In The influenza viruses and influenza 
Edited by: Kilbourne ED. New York: Academic Press; 1975:375-447. 
20. Govorkova EA, Rehg JE, Krauss S, Yen HL, Guan Y, Peiris M, Nguyen TD, 
Hanh TH, Puthavathana P, Long HT, Buranathai C, Lim W, Webster RG, 
Hoffmann E: Lethality to ferrets of H5N1 influenza viruses isolated from 
humans and poultry in 2004.  J Virol 2005, 79:2191-2198.
21. Lipatov AS, Kwon YK, Pantin-Jackwood MJ, Swayne DE: Pathogenesis of 
H5N1 Influenzavirus infections in mice and ferret models differs 
according to respiratory tract or digestive system exposure.  J Infect Dis 
2009, 199:717-725.
22. Maines TR, Lu XH, Erb SM, Edwards L, Guarner J, Greer PW, Nguyen DC, 
Szretter KJ, Chen LM, Thawatsupha P, Chittaganpitch M, Waicharoen S, 
Nguyen DT, Nguyen T, Nguyen HH, Kim JH, Hoang LT, Kang C, Phuong LS, 
Lim W, Zaki S, Donis RO, Cox NJ, Katz JM, Tumpey TM: Avian influenza 
(H5N1) viruses isolated from humans in Asia in 2004 exhibit increased 
virulence in mammals.  J Virol 2005, 79:11788-11800.
23. Zitzow LA, Rowe T, Morken T, Shieh WJ, Zaki S, Katz JM: Pathogenesis of 
avian influenza A (H5N1) viruses in ferrets.  J Virol 2002, 76:4420-4429.
24. Tellier R: Aerosol transmission of influenza A virus: a review of new 
studies.  J R Soc Interface 2009, 6(Suppl 6):783-790.
25. Hinds WC: Aerosol technology: properties, behavior, and measurement of 
airborne particles 2nd edition. New York: John Wiley and Sons, Inc; 1999. 
26. Nicas M, Nazaroff WW, Hubbard A: Toward understanding the risk of 
secondary airborne infection: emission of respirable pathogens.  J 
Occup Environ Hyg 2005, 2:143-154.
27. Xie X, Li Y, Chwang AT, Ho PL, Seto WH: How far droplets can move in 
indoor environments--revisiting the Wells evaporation-falling curve.  
Indoor Air 2007, 17:211-225.
28. Knight V: Airborne transmission and pulmonary deposition of 
respiratory viruses.  In 6th International symposium on aerobiology, 
Airborne transmission and airborne infections Edited by: Hers JF, Winkles KC. 
New York:Wiley; 1973:175-182. 
29. Shinya K, Ebina M, Yamada S, Ono M, Kasai N, Kawaoka Y: Avian flu: 
influenza virus receptors in the human airway.  Nature 2006, 
440:435-436.
30. van Riel D, Munster VJ, de Wit E, Rimmelzwaan GF, Fouchier RA, Osterhaus 
AD, Kuiken T: H5N1 virus attachment to lower respiratory tract.  Science 
2006, 312:399.
31. Yu CP, Diu CK: Total and regional deposition of inhaled aerosols in 
humans.  J Aerosol Sci 1983, 14:599-609.
32. Shinya K, Hatta M, Yamada S, Takada A, Watanabe S, Halfmann P, Horimoto 
T, Neumann G, Kim JH, Lim W, Guan Y, Peiris M, Kiso M, Suzuki T, Suzuki Y, 
Kawaoka Y: Characterization of a human H5N1 influenza A virus 
isolated in 2003.  J Virol 2005, 79:9926-9932.
33. Yamada S, Suzuki Y, Suzuki T, Le MQ, Nidom CA, Sakai-Tagawa Y, 
Muramoto Y, Ito M, Kiso M, Horimoto T, Shinya K, Sawada T, Kiso M, Usui T, 
Murata T, Lin Y, Hay A, Haire LF, Stevens DJ, Russell RJ, Gamblin SJ, Skehel 
JJ, Kawaoka Y: Haemagglutinin mutations responsible for the binding 
of H5N1 influenza A viruses to human-type receptors.  Nature 2006, 
444:378-382.
34. Maher JA, DeStefano J: The ferret: an animal model to study influenza 
virus.  Lab Anim (NY) 2004, 33:50-53.
35. Maines TR, Lu XH, Erb SM, Edwards L, Guarner J, Greer PW, Nguyen DC, 
Szretter KJ, Chen LM, Thawatsupha P, Chittaganpitch M, Waicharoen S, 
Nguyen DT, Nguyen T, Nguyen HH, Kim JH, Hoang LT, Kang C, Phuong LS, 
Lim W, Zaki S, Donis RO, Cox NJ, Katz JM, Tumpey TM: Avian influenza 
(H5N1) viruses isolated from humans in Asia in 2004 exhibit increased 
virulence in mammals.  J Virol 2005, 79:11788-11800.
36. Herlocher ML, Elias S, Truscon R, Harrison S, Mindell D, Simon C, Monto AS: 
Ferrets as a transmission model for influenza: sequence changes in 
HA1 of type A (H3N2) virus.  J Infect Dis 2001, 184:542-546.
Received: 21 May 2010 Accepted: 23 June 2010 
Published: 23 June 2010
This article is available from: http://www.virologyj.com/content/7/1/135 © 2010 Tuttle et al; licensee BioMed Central Ltd.  This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Virology Journal 2010, 7:135Tuttle et al. Virology Journal 2010, 7:135
http://www.virologyj.com/content/7/1/135
Page 12 of 12
37. Herlocher ML, Truscon R, Elias S, Yen HL, Roberts NA, Ohmit SE, Monto AS: 
Influenza viruses resistant to the antiviral drug oseltamivir: 
transmission studies in ferrets.  J Infect Dis 2004, 190:1627-1630.
38. Niven RW: Atomization and nebulization.  In Inhalation Aerosols Edited 
by: Hickey AJ. New York: Dekker; 1996:273-312. 
39. Reed LJ, Muench H: A simple method for estimating fifty percent 
endpoints.  Am J Hyg 1938, 27:493-497.
40. Hamilton SB, Daniels DE, Sosna WA, Jeppesen ER, Owells JM, Halpern MD, 
McCurdy KS, Rayner JO, Lednicky JA: Gas-permeable ethylene bags for 
the small scale cultivation of highly pathogenic avian influenza H5N1 
and other viruses in embryonated chicken eggs.  Virol J 2010, 7:23.
41. Szretter KJ, Balish AL, Katz JM: Influenza: Propagation, quantification, 
and storage.  In Current protocols in microbiology Volume 1. New Jersey: 
John Wiley & Sons, Inc; 2006.  Chapter 15: Unit 15G.1
42. Woolcock PR, McFarland MD, Lai S, Chin RP: Enhanced recovery of avian 
influenza viruses by a combination of chicken embryo inoculation 
methods.  Avian Dis 2001, 45:1030-1035.
43. Guyton A: Measurements of the respiratory volumes of laboratory 
animals.  Am J Physiol 1947, 150:70-77.
44. Gad SC: Animal Models in Toxicology 2nd edition. Edited by: Gad SC. 
Florida: CRC Press; 2006:493-562.  Chapter 7, The ferret
45. Vinegar A, Sinnett EE, Kosch PC, Miller ML: Pulmonary physiology of the 
ferret and its potential as a model for inhalation toxicology.  Lab Anim 
Sci 1985, 35:246-250.
doi: 10.1186/1743-422X-7-135
Cite this article as: Tuttle et al., Design, assembly, and validation of a nose-
only inhalation exposure system for studies of aerosolized viable influenza 
H5N1 virus in ferrets Virology Journal 2010, 7:135